- Adults at least 18 years of age who self-identify as non-white, may qualify to participate.
- Must have a diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before first administration of study drug OR expert panel confirmed psoriasis diagnosis (based on
clinical photos) OR biopsy confirmed psoriasis. - Individuals must also have moderate to severe plaque psoriasis, with involvement of 10% or more body surface area (BSA) OR have moderate to severe scalp psoriasis, with involvement of 30% or more scalp surface area and at least one
plaque outside of the scalp. - Participants will receive investigational treatment (active study drug) or placebo, via injection.
- Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.
- Study participation will last about 116 weeks and involve about 20 visits to the study centre.
If interested, please contact our Research Coordinator at 416-633-0001 x 4 or e-mail [email protected].
